John H. Kempen

faculty photo
Professor of Ophthalmology
Attending Physician and Surgeon, Department of Ophthalmology/Scheie Eye Institute, Presbyterian Hospital
Attending Physician and Surgeon, Department of Ophthalmology, Hospital of the University of Pennsylvania
Director of Ocular Inflammation Service, Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania School of Medicine
Director of Ophthalmic Epidemiology and International Ophthalmology , Department of Ophthalmology, University of Pennsylvania School of Medicine
Member, Center for Preventive Ophthalmology and Biostatistics
Member, University of Pennsylvania Graduate Group in Epidemiology and Biostatistics, University of Pennsylvania Graduate Group in Epidemiology and Biostatistics
Senior Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Member, Institute for Translational Medicine and Therapeutics, University of Pennsylvania
Department: Ophthalmology

Contact information
Ocular Inflammation Service
Scheie Eye Institute
51 N. 39th St
Philadelphia, PA 19104
Education:
BS (Biological Sciences, with Departmental Honors)
Stanford University, 1988.
MD (Medicine)
School of Medicine, University of California, San Diego, 1992.
MPH (International Health)
School of Hygiene & Public Health, Johns Hopkins University, 1997.
MHS (Biostatistics)
School of Hygiene and Public Health, Johns Hopkins University, 1999.
PhD (Epidemiology)
Bloomberg School of Public Health, Johns Hopkins University, 2001.
Permanent link
 

Description of Research Expertise

Dr. Kempen is well-known nationally and internationally as an expert in ocular inflammatory diseases—such as uveitis, scleritis, and others—as well as ocular complications of AIDS. He is the Director of the Penn Ocular Inflammation Service, and Director of Ophthalmic Epidemiology at the Center for Preventive Ophthalmology and Biostatistics. As an expert epidemiologist, he holds a joint appointment in the Department of Biostatistics & Epidemiology, and the Penn Center for Clinical Epidemiology and Biostatistics. Dr. Kempen also is engaged in international research in India and Ethiopia regarding ophthalmic epidemiology and trachoma research.

Clinical Research
-Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study (funded by the National Eye Institute): Dr. Kempen is the national Principal Investigator for this study, the first NIH-sponsored multicenter clinical research study in the field of uveitis.
-Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study(funded by the National Eye Institute): Dr. Kempen serves as International Vice-Chairman for the MUST Network, Protocol Chair for the MUST Trial Follow-up Study, and Director of the Penn Clinical Center enrolling patients in this study.

Key words
Uveitis, iritis, pars planitis, panuveitis, sympathetic ophthalmia, choroiditis, retinitis, neuroretinitis, Vogt-Koyanagi-Harada disease, Fuchs’ heterochromic cyclitis, retinal vasculitis, serpiginous retinochoroiditis, birdshot chorioretinitis, immunosuppressive therapy for eye disease, scleritis, orbital inflammatory disease, ocular complications of AIDS, cytomegalovirus retinitis, acute retinal necrosis, infectious retinitis, toxoplasmic retinitis, trachoma, international ophthalmology, Ethiopia, India

Description of Other Expertise

Dr. Kempen is Co-Founder and President of Sight for Souls, a US 501(c)(3) charity developing self-sustaining, tertiary eye institutes in developing countries as a strategy to address global blindness through self-sustaining service delivery, public health outreach, training and research. Approximately 80% of global blindness and low vision requires individual-level clinical care, which is directly addressed by this strategy.

Description of Itmat Expertise

Dr. Kempen's research focuses on ocular inflammation, ocular complications of AIDS/immunodeficiency, and more generally on the epidemiology and treatment of eye diseases

Selected Publications

McGuire JL, Kempen JH, Localio R, Ellenberg JH, Douglas SD: Immune markers predictive of neuropsychiatric symptoms in HIV-infected youth. Clin Vaccine Immunol 22(1), Jan 2015 Notes: Epub 2014 Oct 29.

Kempen JH, Sugar EA, Varma R, Dunn JP, Heinemann MH, Jabs DA, Lyon AT, Lewis RA: Risk of cataract among subjects with the acquired immune deficiency syndrome free of ocular opportunistic infections Ophthalmology 121(12): 2317-24, Dec 2014 Notes: Epub 2014 Aug 8.

Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study: Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology 121(2): 588-95, Feb 2014 Notes: Epub 2013 Dec 12.

Sen HN, Vitale S, Gangaputra SS, Nussenblatt RB, Liesegang TL, Levy-Clarke GA, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Kempen JH: Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology 121(11): 2275-86, Nov 2014 Notes: Epub 2014 Jul 11.

Mehta S, Linton MM, Kempen JH: Outcomes of cataract surgery in patients with uveitis: a systematic review and Meta-Analysis. Am J Ophthalmol 158(4): 676-692, Oct 2014 Notes: Epub 2014 Jun 28

Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK: Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib. American Journal of Ophthalmology 158(4): 831-837, October 2014 Notes: Epub 2014 Jul 15.

Multiceneter Uveitis Steroid Treatment(MUST) Trial Research Group, Sugar EA, Holbrook JT, Kempen JH, Burke AE, Drye LT, Thorne JE Louis TA, Jabs DA, Altaweel MM, Frick KD: Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis. Ophthalmology 121(10): 1855-62, Oct 2014.

Hornbeak DM, Payal A, Pistilli M, Biswas J, Ganesh SK, Gupta V, Rathinam SR, Davis JL, Kempen JH: Interobserver agreement in clinical grading of vitreous haze using alternative grading scales. Ophthalmology 121(8): 1643-8, Aug 2014 Notes: Epub 2014 Mar 31.

Eftekhari K, Ghodasra DH, Haynes K, Chen J, Kempen JH, Vanderbeek BL: Risk of retinal tear or detachment with oral fluoroquinolone use: a cohort study. Pharmacoepidemiol Drug Saf 23(7): 745-52, Jul 2014 Notes: Epub 2014 Apr 22.

Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS : Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Invest Ophthalmol Vis Sci 55(5): 2993-3002, May 2014.

back to top
Last updated: 07/02/2015
The Trustees of the University of Pennsylvania